STOCK TITAN

Sana Biotechnology (SANA) EVP and CSO exercises 125K RSUs

(Moderate)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Sana Biotechnology, Inc. (SANA) reported insider equity transactions by EVP and Chief Scientific Officer Dhavalkumar Dhirajlal Patel. On August 26, 2026, he exercised 125,000 Restricted Stock Units, receiving 125,000 shares of common stock, and his RSU position was reported as 250,000 units afterward. On August 27, 2026, 41,158 common shares were delivered or withheld at $4.11 per share for payment of exercise price or tax liability related to the equity award.

Positive

  • None.

Negative

  • None.
Insider PATEL DHAVALKUMAR DHIRAJLAL
Role EVP, Chief Scientific Officer
Type Security Shares Price Value
Exercise Price or Tax Liability Common Stock 41,158 $4.11 $169K
Exercise Restricted Stock Units F1, F2 125,000 $0.00 $0.00
Exercise Common Stock 125,000 $0.00 $0.00
Holdings After Transaction: Restricted Stock Units — 250,000 shares (Direct); Common Stock — 183,352 shares (Direct)
Footnotes (2)
  1. F1. Each restricted stock unit represents a contingent right to receive one share of Sana Biotechology, Inc. ("Sana") common stock.
  2. F2. The award vested as to 25% of the restricted stock units on each of August 26, 2025 and 2026, and the remaining restricted stock units will vest in two equal installments on each of August 26, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.
Restricted Stock Units exercised 125,000 units RSUs exercised or converted on August 26, 2026
Common Stock acquired from RSUs 125,000 shares Common shares received on exercise or conversion of RSUs on August 26, 2026
Shares delivered or withheld 41,158 shares Common shares used for payment of exercise price or tax liability on August 27, 2026
Per-share value for F transaction $4.11 per share Price used to value shares delivered or withheld on August 27, 2026
RSUs remaining after transaction 250,000 units Restricted Stock Units position reported after August 26, 2026 transaction
Vesting tranches already vested 25% on August 26, 2025; 25% on August 26, 2026 Two of four annual RSU vesting installments completed
Future vesting installments 2 equal installments Remaining RSUs vest on August 26, 2027 and August 26, 2028, subject to continuous service
Restricted Stock Units financial
"Each restricted stock unit represents a contingent right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
exercise price or tax liability financial
"Payment of exercise price or tax liability by delivering or withholding securities"
continuous service financial
"provided that the reporting person provides continuous service to Sana"
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

FAQ

What insider transactions were reported at Sana Biotechnology (SANA)?

The EVP and Chief Scientific Officer, Dhavalkumar Dhirajlal Patel, exercised 125,000 Restricted Stock Units into 125,000 common shares on August 26, 2026, and on August 27, 2026, 41,158 common shares were delivered or withheld to pay the exercise price or tax liability.

How many Sana (SANA) RSUs did the EVP exercise and what did he receive?

On August 26, 2026, the EVP exercised 125,000 Restricted Stock Units, each representing a right to receive one share of Sana common stock, and received 125,000 common shares as a result of this exercise or conversion.

How many Sana (SANA) shares were withheld for taxes or exercise price?

On August 27, 2026, 41,158 shares of common stock were delivered or withheld at $4.11 per share as payment of the exercise price or tax liability associated with the insider’s equity award.

What RSU balance was reported after the Sana (SANA) insider transaction?

After the August 26, 2026 transaction, the reporting person’s Restricted Stock Unit position was listed as 250,000 RSUs, each representing a contingent right to receive one share of Sana common stock, subject to the stated vesting conditions.

What is the vesting schedule for the Sana (SANA) RSU award in this filing?

The award vested as to 25% of the RSUs on August 26, 2025 and 25% on August 26, 2026. The remaining RSUs will vest in two equal installments on August 26, 2027 and August 26, 2028, if continuous service to Sana is maintained.

Was the Sana (SANA) insider transaction under a Rule 10b5-1 plan?

The filing’s Rule 10b5-1 checkbox is not checked, and there is no footnote indicating that the transactions were made pursuant to a Rule 10b5-1 or other pre-arranged trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
PATEL DHAVALKUMAR DHIRAJLAL

(Last)(First)(Middle)
C/O SANA BIOTECHNOLOGY, INC.
188 EAST BLAINE STREET, SUITE 350

(Street)
SEATTLE WASHINGTON 98102

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Sana Biotechnology, Inc. [ SANA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
EVP, Chief Scientific Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/26/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/26/2026M125,000A$0.00224,510D
Common Stock08/27/2026F41,158D$4.11183,352D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units(1)08/26/2026M125,000 (2) (2)Common Stock125,000$0.00250,000D
Explanation of Responses:
1. Each restricted stock unit represents a contingent right to receive one share of Sana Biotechology, Inc. ("Sana") common stock.
2. The award vested as to 25% of the restricted stock units on each of August 26, 2025 and 2026, and the remaining restricted stock units will vest in two equal installments on each of August 26, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.
Remarks:
/s/ Aaron M. Grossman, Attorney-in-Fact for Dhavalkumar Dhirajlal Patel08/27/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)